Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a ...

SOUTH SAN FFRANCISCO, CA, USA and BAGSVAERD, Denmark I May 14, 2025 I Septerna, Inc. (Nasdaq: SEPN) and Novo Nordisk today announced an exclusive global ...

About GABAB Activation with PAM: Activation of gamma-aminobutyric acid subtype B (GABAB) receptor, a Family C class of GPCR, is clinically and commercially validated ... company focused on developing ...

Activation of gamma-aminobutyric acid subtype B (GABAB) receptor, a Family C class of GPCR, is clinically and commercially validated ... Addex is a clinical-stage biopharmaceutical company focused on ...

About GABAB Activation with PAM: Activation of gamma-aminobutyric acid subtype B (GABAB) receptor, a Family C class of GPCR ... of novel small molecule allosteric modulators for neurological ...

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio ...

Collaboration combines Novo Nordisk's scientific leadership in obesity and cardiometabolic diseases with Septerna's expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to develop mul ...

SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today ...